Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Slattery

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Pharmaceutical Research|April 1, 1993
Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S)Y H Park, P R Mayer, R Barker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patientsJ T Slattery, T F Kalhorn, G B McDonald, et al.
Bone Marrow Transplantation|May 9, 2000
An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic diseaseA M Bolinger, A B Zangwill, J T Slattery, et al.
Bone Marrow Transplantation|January 10, 2002
Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantationA M Bolinger, A B Zangwill, J T Slattery, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazidJ Y Chien, R M Peter, C M Nolan, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1996
Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouseG D Bennett, B M Amore, R H Finnell, et al.
BMC Medicine|June 1, 2007
The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized studyE K Kuffner, J L Green, G M Bogdan, et al.
Bone Marrow Transplantation|April 1, 1996
Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levelsT Demirer, C D Buckner, F R Appelbaum, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 1, 1997
Characterization of carbamazepine metabolism in a mouse model of carbamazepine teratogenicityB M Amore, T F Kalhorn, G L Skiles, et al.
Bone Marrow Transplantation|August 22, 2002
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantationJ S McCune, T Gooley, J P Gibbs, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Pharmaceutical Research|April 1, 1993
Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S)Y H Park, P R Mayer, R Barker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patientsJ T Slattery, T F Kalhorn, G B McDonald, et al.
Bone Marrow Transplantation|May 9, 2000
An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic diseaseA M Bolinger, A B Zangwill, J T Slattery, et al.
Bone Marrow Transplantation|January 10, 2002
Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantationA M Bolinger, A B Zangwill, J T Slattery, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazidJ Y Chien, R M Peter, C M Nolan, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1996
Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouseG D Bennett, B M Amore, R H Finnell, et al.
BMC Medicine|June 1, 2007
The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized studyE K Kuffner, J L Green, G M Bogdan, et al.
Bone Marrow Transplantation|April 1, 1996
Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levelsT Demirer, C D Buckner, F R Appelbaum, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 1, 1997
Characterization of carbamazepine metabolism in a mouse model of carbamazepine teratogenicityB M Amore, T F Kalhorn, G L Skiles, et al.
Bone Marrow Transplantation|August 22, 2002
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantationJ S McCune, T Gooley, J P Gibbs, et al.
Pageof 12